Indivior UK Limited

Glaxo Group Limited

Glaxogrouplimited

Chronos Therapeutics Limited

Glaxosmithkline LLC

Luca Tarsi

Fabrizio Micheli

Susanna Cremonesi

Teresa Semeraro

Dieter Hamprecht

Silvia Terreni

Romano Di Fabio

Giorgio Bonanomi

Giovanna Tedesco

Gabriella Gentile

Federica Damiani

Barbara Bertani

Anna Maria Capelli

Luca Arista

Elettra Fazzolari

Karl Richard Gibson

Giovanni Gaviraghi

Daniele Andreotti

Colin Philip Leslie

Alessandra Pasquarello

Tino Rossi

Stefano Biondi

Anna Checchia

Alfonso Pozzan

Aldo Feriani

Domenica Antonia Pizzi

Emiliangelo Ratti

Gabriella Finizia

Tim Luker

Teresa Semerano

Timothy Jon Luker

Riccardo Zanaletti

Luca Raveglia

Susana Cremonesi

Dieter Wolfgang Hamprecht

There is provided a compound of formula (I), wherein Lto L', Rto R, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.

Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists

The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.

Dopamine Dreceptor antagonist compounds

The disclosure provides compounds having formula (I), where the substituents are as defined herein. The compounds are useful for modulating the dopamine D3 receptor and for treating conditions associated therewith, such as addictions, drug dependency, and psychiatric conditions.

Substituted 3,6-diazabicyclo[3.2.0]heptanes

The disclosure provides compounds of formula (I) or pharmaceutically acceptable salts thereof: The disclosure also provides processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them, and their use as modulators of dopamine Dreceptors, such as treating substance abuse or psychiatric diseases. 

Dopamine D3 receptor antagonists having a morpholine moiety

The disclosure provides compounds having formula (I), wherein the substituents are as defined herein. The compounds are useful for modulating the dopamine Dreceptor and for treating conditions associated therewith, such as addictions, drug dependency, and psychiatric conditions. 

Substituted hexahydropyrrolo[3,4-b]pyrroles and hexahydrocyclopenta[c]pyrroles as dopamine receptor modulators

Dopamine D3 receptor antagonists

Dopamine D3 receptor antagonist compounds

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R, R, R, R, R, R, R, R, R, R, m, n, A, L and B are as defined herein. 

N-(hetero)aryl-substituted heteroyclic derivatives useful for the treatment of diseases or conditions related to the central nervous system

The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein

[object Object]

The present invention relates to compounds of formula (I) or salts thereof wherein A, X, R, Rand n are defined herein, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine Dreceptors, e.g., to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, premature ejaculation or to enhance cognition.

Spirocompounds useful as modulators for dopamine D3 receptors

Compounds of formula (I) or a salt thereof are disclosed: wherein Ris pyrazolyl substituted by two or three substituents independently selected from halogen, Calkyl and haloCalkyl; Ris hydrogen or methyl; and Ris quinolinyl, oxazolyl or phenyl, each of which is optionally substituted by one or two halogen, Calkyl or haloCalkyl. Processes for preparation and uses of the compounds in medicine, for example for the treatment of schizophrenia or drug dependency, are also disclosed.

7-pyrazolylbenzazepines having affinity for D3 receptor

Compounds of formula (I) wherein A is a 5 or 6 membered heteroaromatic ring or a 5 or 6 membered heterocyclic ring, and which are useful for treating mental disorders such as schizophrenia are set out herein.

Compounds having affinity for dopamine D3 receptor and uses thereof

The present invention relates to novel compounds of formula (I) or pharmaceutically acceptable salt thereof: processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine Dreceptors, e.g. to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, premature ejaculation or cognition impairment.

3-(1,2,4-triazol-3-ylalkyl) azabicyclo (3.1.0) hexane derivatives as modulators of dopamine D3 receptors

The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof: 

The present invention relates to novel compounds of formula (I) or a salt thereof: wherein:

Triazole derivatives as modulators of dopamine D3 receptors

Growing community of inventors

Verona, Italy

Luca Tarsi